EUCTR2011-003574-84-GB进行中（未招募）1 期
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 185
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female =18 years old
- •2. Life expectancy of at least 12 weeks
- •3. ECOG Performance Status of 0 or 1
- •4. Histologically confirmed unresectable advanced or metastatic hepatocellular carcinoma (without fibrolamellar subtype) patients who are not candidate for or progressed on loco-regional therapy
- •5. Prior treatment with at least 1 systemic agent, (such as Sorafenib or other experimental agents), with documented progressive disease after systemic agent(s), or documented adverse event(s) associated with prior systemic agent(s) that resulted in discontinuance of that(those) agent(s)
- •6. Not a candidate for curative treatments (e.g. resection, transplantation)
- •7. Child-Pugh A ( score of 5-6)
- •8. Adequate hematologic function: Platelet count = 50x 109/L, Absolute Neutrophil Count = 1,500/µL, Hemoglobin = 8.0 g /dL
- •9. Adequate hepatic function: ALT (SGPT), AST (SGOT) = 5 x ULN, Bilirubin = 2 mg/ dL
- •10. Adequate renal function: Serum Creatinine = 2 x ULN or calculated Creatinine Clearance = 60 ml/min using Cockcroft and Gault formula
- •11. Ability to provide, for central review, a tumor tissue sample containing at least 5 % tumor cells to determine the level of GPC-3 expression by IHC. Determination of GPC-3 expression level is required prior to study entry.
- •12. Patients must have recovered from effects of any major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
- •13. Measurable disease (by RECIST 1.1) prior to the administration of study treatment
- •14. Negative serum pregnancy test
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 86
排除标准
- •1. Child-Pugh B or C
- •2. Known HCC with fibro-lamellar histology
- •3. Known brain or leptomeningeal metastases
- •4. Patients with a previous malignancy within the past 5 years are excluded(patients who had curatively treated basal cell carcinoma of the skin,early gastrointestinal cancer by endoscopic resection, and/or insitu carcinoma of the cervix and other malignancies which were considered cured and deemed by the PI to have no impact on the PFS and OS are allowed after discussion with the study medical monitor)
- •5. Active infectious diseases requiring treatment except for hepatitis B and C
- •6. NCI CTCAE version 4.0 grade 3 hemorrhage within 4 weeks of starting the study treatment
- •7. History of organ allograft including liver transplant
- •8. Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study
- •9. Patient who have had any anticancer treatment within 2 weeks prior to entering the study
- •10. Patients who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies
- •11. Patients receiving Interferon therapy
- •12. Patients with baseline QTc > 470 ms, or patients with baseline resting bradycardia <45 beats per minutes.
- •13. Patients who received anticoagulation or thrombolytic agents for therapeutic purposes (except for low-dose administration for catheter clearance or for prophylactic purposes) within 2 weeks prior to Day 1
研究者
相似试验
已完成
不适用
enzilumab Study in Healthy Korean SubjectsCodes for special purposesKCT0006851Telcon RF Pharmaceuticals20
已完成
不适用
A human study to Investigate the Effect of L.lactis CKDB001 Administration on Liver Aminotransferases in Subjects with Nonalcoholic Fatty Liver DiseaseKCT0007388Chong Kun Dang Bio120
尚未招募
不适用
A Randomized, Double-blinded, Placebo-controlled, Multi-center Phase 2 Study to Explore the Efficacy and Safety of Subcutaneous Injection EG-Myocin Immediately Before and After PCI in Patients with Acute ST-Elevation Myocardial Infarction (STEMI)KCT0004288Eyegene60
招募中
1 期
Trial to evaluate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia PatientsCOVID-19 Pneumonia PatientsMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2022-001152-42-BGShaperon, Inc.1,134
进行中（未招募）
1 期
Multi-centre Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects with Type 2 Diabetes and Nephropathydiabetic nephropathyEUCTR2019-004155-37-CZAptabio Therapeutics, Inc140